The Popcorn platform is a first-in-class modular therapeutic oncolytic adenovirus delivery system designed to produce single-domain functional antibodies against any chosen target within the tumor microenvironment, accelerating translation across tumor types.
DMG is not just rare and aggressive — it occupies the brainstem, making surgical resection impossible and conventional drug delivery irrelevant.
Patients remain mentally aware while progressively losing vital functions: vision, swallowing, movement, breathing.
Radiotherapy, chemotherapy, targeted therapies, and adult immunotherapy have all failed. There is currently no effective treatment.
POP02 is built on DNX2401 — an oncolytic adenovirus with established human safety and demonstrated anti-tumor activity in peer-reviewed Phase I trials.
First demonstration of DNX2401 efficacy in DMG preclinical models
Phase I clinical trial proving safety and preliminary efficacy in humans
Built on DNX2401, the only oncolytic adenovirus with proven clinical activity in high-grade gliomas — including compassionate-use data in pediatric DMG.
Single-domain antibody (sdAb) payload is interchangeable — the same viral chassis can be re-armed against different immune targets with minimal re-engineering.
Direct intratumoral delivery bypasses the blood–brain barrier — the major pharmacological obstacle that has defeated all systemic therapies in DMG.
Adenovirus vectors carry an established pediatric safety record. No DNA integration risk. POP02 replication is restricted to H3K27M-mutant tumor cells.
Orphan Drug Designation eligibility (FDA + EMA) provides 10-year market exclusivity, priority review, and fee waivers. Breakthrough Therapy application planned post-Phase I proof-of-concept.
Scroll to browse publications
POP02 is our lead program targeting pediatric DMG, with platform expansion into adult GBM already in preclinical development.